- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07506863
Een studie naar de werkzaamheid, farmacokinetiek en veiligheid van Mitapivat bij pediatrische deelnemers met transfusieafhankelijke alfa- of bèta-thalassemie (α- of β-TDT) (ENERGIZEKids-T)
Een fase 3, dubbelblinde, gerandomiseerde, placebo-gecontroleerde, multicenterstudie naar de werkzaamheid, farmacokinetiek en veiligheid van Mitapivat bij pediatrische proefpersonen met α- of β-transfusieafhankelijke thalassemie
The primary objective of this study is to compare the effect of mitapivat versus placebo on transfusion burden in pediatric participants with α- or β-transfusion-dependent thalassemia.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Agios Medical Affairs
- Telefoonnummer: 833-228-8474
- E-mail: medinfo@agios.com
Studie Locaties
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Werving
- Emory-Children's Center/ Children's Healthcare of Atlanta: Arthur M. Blank Hospital
-
-
New York
-
New York, New York, Verenigde Staten, 10065
- Werving
- Weill Cornell Medical College/ New York Presbyterian
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104-4318
- Werving
- Children's Hospital of Philadelphia
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75390
- Werving
- University of Texas Southwestern Medical Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Written informed consent/assent from the participant (or their legally authorized representative, parent(s), or legal guardian) must be obtained before any study-related procedures are conducted and participants must be willing to comply with all study procedures for the duration of the study.
- Aged 1 to <18 years and weighing at least 7 kilograms (kg) at the time of providing informed consent/assent.
- Documented diagnosis of thalassemia (β-thalassemia with or without α-globin gene mutations, hemoglobin E (HbE)/β-thalassemia, or α-thalassemia/hemoglobin H (HbH) disease) based on Hemoglobin (Hb) electrophoresis, Hb high-performance liquid chromatography, and/or DNA analysis from the participant's medical record. If this information is not available from the participant's medical record, the test(s) can be performed by a local laboratory during the Screening Period. If a local laboratory is unable to perform the test(s), results from the comprehensive α- and β-globin genotyping performed by the study central laboratory can be used.
- Transfusion dependent, defined as 6 to 20 transfusion episodes (also referred to as "transfusion events") and a ≤6-week transfusion-free period during the 24-week period before randomization.
- If taking hydroxyurea, the hydroxyurea dose must be stable for ≥16 weeks before randomization.
- Female participants who have attained menarche must be abstinent of sexual activities that may induce pregnancy as part of their usual lifestyle, or agree to use 2 forms of contraception, 1 of which must be considered highly effective, from the time of informed consent/assent, throughout the study, and for 28 days after the last dose of study drug. The second form of contraception can include an acceptable barrier method.
Exclusion Criteria:
-
Pregnant or breastfeeding.
-
Documented history of homozygous or heterozygous hemoglobin S (HbS) or hemoglobin C (HbC).
-
Prior exposure to gene therapy or prior bone marrow or stem cell transplantation, including any prior exposure to myeloablative chemotherapy.
-
Any conditions other than thalassemia expected to affect sexual maturation.
-
Currently receiving treatment with luspatercept; the last dose must have been administered ≥36 weeks before randomization.
-
Currently receiving treatment with hematopoietic stimulating agents; the last dose must have been administered ≥36 weeks before randomization.
-
History of malignancy (active or treated) ≤5 years before providing informed consent/assent, except for nonmelanomatous skin cancer in situ, cervical carcinoma in situ, or breast carcinoma in situ.
-
History of active and/or uncontrolled cardiac or pulmonary disease or clinically relevant QT prolongation within 6 months before providing informed consent/assent.
-
Hepatobiliary disorders, including but not limited to:
- Liver disease with histopathological evidence or clinical diagnosis of cirrhosis or severe fibrosis.
- Clinically symptomatic cholelithiasis or cholecystitis (prior cholecystectomy is not exclusionary).
- History of drug-induced cholestatic hepatitis.
- Aspartate Aminotransferase (AST) >2.5*Upper Limit of Normal (ULN) (unless due to hemolysis and hepatic iron deposition) and Alanine Transaminase (ALT) >2.5*ULN (unless due to hepatic iron deposition).
-
Renal dysfunction as defined by an estimated glomerular filtration rate <60 milliliters per minute (mL/min)/1.73-meter square (m^2).
-
Nonfasting triglycerides >215 milligrams per deciliter (mg/dL) [5 millimole per liter (mmol/L)].
-
Active infection requiring systemic antimicrobial therapy at the time of providing informed consent/assent. If antimicrobial therapy is required during the Screening Period, screening procedures should not be performed while antimicrobial therapy is being administered, and the last dose of antimicrobial therapy must be administered ≥7 days before randomization.
-
Participants with known active hepatitis B or hepatitis C virus infection.
-
Participants with known human immunodeficiency virus (HIV) infection.
-
History of major surgery (including splenectomy) ≤ 6 months before providing informed consent/assent and/or a major surgical procedure planned during the study.
-
Current enrollment or past participation (within ≤12 weeks or a timeframe equivalent to 5 half-lives of the investigational study drug before administration of the first dose of study drug, whichever is longer) in any other clinical study involving an investigational treatment or device.
-
Receiving strong Cytochrome3A4/5 (CYP3A4/5) inhibitors that have not been stopped for ≥5 days or a timeframe equivalent to 5 half-lives (whichever is longer), or strong CYP3A4/5 inducers that have not been stopped for ≥4 weeks or a timeframe equivalent to 5 half-lives (whichever is longer), before randomization.
-
Receiving anabolic steroids that have not been stopped for at least 4 weeks before randomization. Testosterone replacement therapy to treat hypogonadism is allowed; the testosterone dose and preparation must be stable for ≥12 weeks before randomization.
-
Known allergy, or other contraindication, to mitapivat or its excipients (microcrystalline cellulose, croscarmellose sodium, sodium stearyl fumarate, mannitol, magnesium stearate, and the Opadry filmcoat [hypromellose, titanium dioxide, lactose monohydrate triacetin, and FD&C Blue #2]).
-
Any medical, hematological, psychological, or behavioral condition(s) or prior or current therapy that, in the opinion of the Investigator, may confer an unacceptable risk to participating in the study and/or could confound the interpretation of the study data. Also excluded are:
- Participants who are institutionalized by regulatory or court order.
- Participants with any condition(s) that could create undue influence (including but not limited to incarceration, involuntary psychiatric confinement, and financial or familial affiliation with the Investigator or Sponsor).
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Mitapivat
Participants will receive oral mitapivat twice daily (BID), with dose determined by age and weight, for 48 weeks during the double blind (DB) period. Enrollment is conducted sequentially by age cohort, beginning with the oldest cohort. Cohort 1: 12 to <18 years Cohort 2: 6 to <12 years Cohort 3: 1 to <6 years Participants who complete the DB period may continue receiving mitapivat in the open label extension (OLE) period for up to 144 weeks. |
Tablets or Granules
Andere namen:
|
|
Placebo-vergelijker: Placebo
Participants will receive oral placebo matching mitapivat, administered BID, with dosing based on age and weight, for 48 weeks during the DB period. Enrollment is conducted sequentially by age cohort, beginning with the oldest cohort. Cohort 1: 12 to <18 years Cohort 2: 6 to <12 years Cohort 3: 1 to <6 years Participants who complete the DB period may transition to receive mitapivat in the OLE period for up to 144 weeks. |
Tablets or Granules
Andere namen:
Tablets or Granules |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of Participants Who Achieved Transfusion Reduction Response (TRR) Through Week 48
Tijdsspanne: Baseline, through Week 48
|
TRR is defined as ≥50 percent (%) reduction in transfused red blood cells (RBC) volume (normalized by weight) in any consecutive 12-week period through Week 48 compared with historical RBC transfusion volume (normalized by weight) and standardized to 12 weeks. |
Baseline, through Week 48
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage verandering in getransfundeerd RBC-volume (genormaliseerd op gewicht) van week 13 tot week 48 vergeleken met historisch transfusievolume (genormaliseerd op gewicht) en gestandaardiseerd naar 36 weken
Tijdsspanne: Uitgangswaarde, Week 13 tot en met Week 48
|
Uitgangswaarde, Week 13 tot en met Week 48
|
|
|
Verandering in het aantal transfusie-episodes van week 13 tot en met week 48 vergeleken met het historische aantal transfusie-episodes gestandaardiseerd op 36 weken
Tijdsspanne: Baseline, Week 13 tot Week 48
|
Baseline, Week 13 tot Week 48
|
|
|
Verandering vanaf de uitgangswaarde in serumijzer na 48 weken
Tijdsspanne: Baseline, Week 48
|
Baseline, Week 48
|
|
|
Verandering ten opzichte van baseline in totale ijzerbindingscapaciteit na 48 weken
Tijdsspanne: Baseline, week 48
|
Baseline, week 48
|
|
|
Verandering vanaf baseline in transferrine op week 48
Tijdsspanne: Baseline, Week 48
|
Baseline, Week 48
|
|
|
Verandering vanaf baseline in transferrineverzadiging bij week 48
Tijdsspanne: Baseline, week 48
|
Baseline, week 48
|
|
|
Verandering vanaf baseline in serumferritinegehalte na 48 weken
Tijdsspanne: Baseline, week 48
|
Baseline, week 48
|
|
|
Cohort 1: Verandering vanaf baseline in oestradiol tot week 48
Tijdsspanne: Baseline, door Week 48
|
Baseline, door Week 48
|
|
|
Cohort 1: Verandering ten opzichte van baseline in estron tot week 48
Tijdsspanne: Baseline, tot en met week 48
|
Baseline, tot en met week 48
|
|
|
Cohort 1: Verandering ten opzichte van de uitgangswaarde in totaal testosteron tot week 48
Tijdsspanne: Baseline, tot en met week 48
|
Baseline, tot en met week 48
|
|
|
Cohort 1: Verandering van baseline in vrij testosteron tot week 48
Tijdsspanne: Baseline, tot en met week 48
|
Baseline, tot en met week 48
|
|
|
Cohort 1: Verandering vanaf baseline in luteïniserend hormoon tot week 48
Tijdsspanne: Baseline, tot en met week 48
|
Baseline, tot en met week 48
|
|
|
Cohort 1: Verandering ten opzichte van de baseline in seksuele rijpheid met het Tannerstadium tot week 48
Tijdsspanne: Baseline, tot en met Week 48
|
Baseline, tot en met Week 48
|
|
|
Verandering ten opzichte van de uitgangswaarde over tijd in Z-score voor lengte naar leeftijd, Z-score voor gewicht naar leeftijd en Z-score voor Body Mass Index (BMI) naar leeftijd tot week 48
Tijdsspanne: Baseline, tot en met week 48
|
Baseline, tot en met week 48
|
|
|
Verandering ten opzichte van de baseline in botmineraaldichtheid (BMD) tot week 48
Tijdsspanne: Baseline, tot en met week 48
|
Baseline, tot en met week 48
|
|
|
Aantal deelnemers met behandeling-gerelateerde bijwerkingen (AEs) en ernstige bijwerkingen (SAEs)
Tijdsspanne: Vanaf de eerste dosis van het studiegeneesmiddel tot het einde van de studie (tot week 196)
|
Vanaf de eerste dosis van het studiegeneesmiddel tot het einde van de studie (tot week 196)
|
|
|
Plasmaconcentratie van Mitapivat
Tijdsspanne: Voorafgaand aan de dosis, en op meerdere tijdstippen (tot 7 uur na toediening) in week 4
|
Voorafgaand aan de dosis, en op meerdere tijdstippen (tot 7 uur na toediening) in week 4
|
|
|
Oppervlakte onder de plasmaconcentratie-tijdcurve van tijd nul tot de laatste kwantificeerbare concentratie (AUC0-last) van Mitapivat
Tijdsspanne: Vóór de dosis, en op meerdere tijdstippen (tot 7 uur na de dosis) in week 4
|
Vóór de dosis, en op meerdere tijdstippen (tot 7 uur na de dosis) in week 4
|
|
|
Maximaal geobserveerde plasmaconcentratie (Cmax) van Mitapivat
Tijdsspanne: Voor toediening, en op meerdere tijdstippen (tot 7 uur na toediening) in week 4
|
Voor toediening, en op meerdere tijdstippen (tot 7 uur na toediening) in week 4
|
|
|
Tijd tot het bereiken van de maximale waargenomen plasmaconcentratie (Tmax) van Mitapivat
Tijdsspanne: Pre-dosis, en op meerdere tijdstippen (tot 7 uur na dosis) in week 4
|
Pre-dosis, en op meerdere tijdstippen (tot 7 uur na dosis) in week 4
|
|
|
Cohort 1: Percentage vrouwelijke deelnemers met nieuw ontwikkelde ovariumcysten tot week 48
Tijdsspanne: Baseline, tot en met week 48
|
Baseline, tot en met week 48
|
|
|
Percentage of Participants Who Achieved TRR2 From Week 13 to Week 24
Tijdsspanne: Baseline, Week 13 through Week 24
|
TRR2 is defined as ≥50% reduction in transfused RBC volume (normalized by weight) from week 13 to week 24 compared with historical RBC transfusion volume (normalized by weight) and standardized to 12 weeks. |
Baseline, Week 13 through Week 24
|
|
Percentage of Participants Who Achieved TRR3 From Week 25 to Week 36
Tijdsspanne: Baseline, Week 25 through Week 36
|
TRR3 is defined as ≥50% reduction in transfused RBC volume (normalized by weight) from week 25 to week 36 compared with historical RBC transfusion volume (Normalized by Weight) and standardized to 12 weeks. |
Baseline, Week 25 through Week 36
|
|
Percentage of Participants Who Achieved TRR4 From Week 37 to Week 48
Tijdsspanne: Baseline, Week 37 through Week 48
|
TRR4 is defined as ≥50% reduction in transfused RBC volume (normalized by weight) from week 37 to week 48 compared with historical RBC transfusion volume (normalized by weight) and standardized to 12 weeks. |
Baseline, Week 37 through Week 48
|
|
Percentage of Participants Who Achieved TRR5 From Week 25 to Week 48
Tijdsspanne: Baseline, Week 25 through Week 48
|
TRR5 is defined as ≥50% reduction in transfused RBC volume (normalized by weight) from week 25 to week 48 compared with historical RBC transfusion volume (normalized by weight) and standardized to 24 weeks. |
Baseline, Week 25 through Week 48
|
|
Percentage of Participants Who Achieved Transfused Independence Through Week 48
Tijdsspanne: Baseline, through Week 48
|
Transfusion independence is defined as transfusion-free for greater than or equal to 8 consecutive weeks through Week 48. |
Baseline, through Week 48
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- AG348-C-029
- 2025-524707-71-00 (Ctis)
- 2025 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .